vs
Enact Holdings, Inc.（ACT）与Prestige Consumer Healthcare Inc.（PBH）财务数据对比。点击上方公司名可切换其他公司
Enact Holdings, Inc.的季度营收约是Prestige Consumer Healthcare Inc.的1.1倍（$312.1M vs $283.4M），Enact Holdings, Inc.净利率更高（53.8% vs 16.5%，领先37.4%），Enact Holdings, Inc.同比增速更快（1.7% vs -2.4%），过去两年Enact Holdings, Inc.的营收复合增速更高（2.2% vs 1.2%）
Enact Holdings, Inc.是美国领先的私人抵押贷款保险服务商，为银行、信用社等各类住宅抵押贷款机构提供风险缓释解决方案，帮助首付较低的购房者获得可负担的住房贷款，助力更多美国普通消费者实现安居需求。
Prestige Consumer Healthcare Inc.是一家美国企业，主营非处方健康护理产品及家用清洁产品的营销与分销业务。该公司于1996年由Medtech Products、Prestige Brands International及Spic and Span三家公司合并成立，总部位于纽约州塔里敦，在弗吉尼亚州林奇堡设有生产工厂。
ACT vs PBH — 直观对比
营收规模更大
ACT
是对方的1.1倍
$283.4M
营收增速更快
ACT
高出4.1%
-2.4%
净利率更高
ACT
高出37.4%
16.5%
两年增速更快
ACT
近两年复合增速
1.2%
损益表 — Q1 FY2026 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $312.1M | $283.4M |
| 净利润 | $168.0M | $46.7M |
| 毛利率 | — | 55.5% |
| 营业利润率 | — | 29.1% |
| 净利率 | 53.8% | 16.5% |
| 营收同比 | 1.7% | -2.4% |
| 净利润同比 | 1.2% | -23.5% |
| 每股收益（稀释后） | $1.18 | $0.97 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACTPBH
| Q1 26 | $312.1M | — | ||
| Q4 25 | $312.7M | $283.4M | ||
| Q3 25 | $311.5M | $274.1M | ||
| Q2 25 | $304.9M | $249.5M | ||
| Q1 25 | $306.8M | $296.5M | ||
| Q4 24 | $301.8M | $290.3M | ||
| Q3 24 | $309.6M | $283.8M | ||
| Q2 24 | $298.8M | $267.1M |
净利润ACTPBH
| Q1 26 | $168.0M | — | ||
| Q4 25 | — | $46.7M | ||
| Q3 25 | — | $42.2M | ||
| Q2 25 | — | $47.5M | ||
| Q1 25 | — | $50.1M | ||
| Q4 24 | — | $61.0M | ||
| Q3 24 | — | $54.4M | ||
| Q2 24 | — | $49.1M |
毛利率ACTPBH
| Q1 26 | — | — | ||
| Q4 25 | — | 55.5% | ||
| Q3 25 | — | 55.3% | ||
| Q2 25 | — | 56.2% | ||
| Q1 25 | — | 57.3% | ||
| Q4 24 | — | 55.5% | ||
| Q3 24 | — | 55.5% | ||
| Q2 24 | — | 54.7% |
营业利润率ACTPBH
| Q1 26 | — | — | ||
| Q4 25 | 71.3% | 29.1% | ||
| Q3 25 | 67.4% | 29.1% | ||
| Q2 25 | 70.4% | 28.8% | ||
| Q1 25 | 68.9% | 29.8% | ||
| Q4 24 | 68.9% | 31.7% | ||
| Q3 24 | 74.1% | 29.7% | ||
| Q2 24 | 78.6% | 27.0% |
净利率ACTPBH
| Q1 26 | 53.8% | — | ||
| Q4 25 | — | 16.5% | ||
| Q3 25 | — | 15.4% | ||
| Q2 25 | — | 19.0% | ||
| Q1 25 | — | 16.9% | ||
| Q4 24 | — | 21.0% | ||
| Q3 24 | — | 19.2% | ||
| Q2 24 | — | 18.4% |
每股收益（稀释后）ACTPBH
| Q1 26 | $1.18 | — | ||
| Q4 25 | $1.23 | $0.97 | ||
| Q3 25 | $1.10 | $0.86 | ||
| Q2 25 | $1.11 | $0.95 | ||
| Q1 25 | $1.08 | $1.00 | ||
| Q4 24 | $1.05 | $1.22 | ||
| Q3 24 | $1.15 | $1.09 | ||
| Q2 24 | $1.16 | $0.98 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $549.0M | $62.4M |
| 总债务越低越好 | $744.9M | $1.0B |
| 股东权益账面价值 | $5.3B | $1.8B |
| 总资产 | $7.0B | $3.5B |
| 负债/权益比越低杠杆越低 | 0.14× | 0.56× |
8季度趋势，按日历期对齐
现金及短期投资ACTPBH
| Q1 26 | $549.0M | — | ||
| Q4 25 | $582.5M | $62.4M | ||
| Q3 25 | $545.6M | $119.1M | ||
| Q2 25 | $616.0M | $139.5M | ||
| Q1 25 | $639.0M | $97.9M | ||
| Q4 24 | $602.8M | $50.9M | ||
| Q3 24 | $674.9M | $51.5M | ||
| Q2 24 | $711.3M | $34.3M |
总债务ACTPBH
| Q1 26 | $744.9M | — | ||
| Q4 25 | $744.5M | $1.0B | ||
| Q3 25 | $744.1M | $993.1M | ||
| Q2 25 | $743.8M | $992.7M | ||
| Q1 25 | $743.4M | $992.4M | ||
| Q4 24 | $743.0M | $992.0M | ||
| Q3 24 | $742.7M | $1.1B | ||
| Q2 24 | $742.4M | $1.1B |
股东权益ACTPBH
| Q1 26 | $5.3B | — | ||
| Q4 25 | $5.4B | $1.8B | ||
| Q3 25 | $5.3B | $1.8B | ||
| Q2 25 | $5.2B | $1.9B | ||
| Q1 25 | $5.1B | $1.8B | ||
| Q4 24 | $5.0B | $1.8B | ||
| Q3 24 | $5.0B | $1.7B | ||
| Q2 24 | $4.8B | $1.7B |
总资产ACTPBH
| Q1 26 | $7.0B | — | ||
| Q4 25 | $6.9B | $3.5B | ||
| Q3 25 | $6.9B | $3.4B | ||
| Q2 25 | $6.8B | $3.4B | ||
| Q1 25 | $6.7B | $3.4B | ||
| Q4 24 | $6.5B | $3.3B | ||
| Q3 24 | $6.6B | $3.3B | ||
| Q2 24 | $6.3B | $3.3B |
负债/权益比ACTPBH
| Q1 26 | 0.14× | — | ||
| Q4 25 | 0.14× | 0.56× | ||
| Q3 25 | 0.14× | 0.54× | ||
| Q2 25 | 0.14× | 0.54× | ||
| Q1 25 | 0.15× | 0.54× | ||
| Q4 24 | 0.15× | 0.55× | ||
| Q3 24 | 0.15× | 0.61× | ||
| Q2 24 | 0.15× | 0.65× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $78.3M |
| 自由现金流经营现金流 - 资本支出 | — | $75.3M |
| 自由现金流率自由现金流/营收 | — | 26.6% |
| 资本支出强度资本支出/营收 | — | 1.1% |
| 现金转化率经营现金流/净利润 | — | 1.68× |
| 过去12个月自由现金流最近4个季度 | — | $267.2M |
8季度趋势，按日历期对齐
经营现金流ACTPBH
| Q1 26 | — | — | ||
| Q4 25 | $724.5M | $78.3M | ||
| Q3 25 | $192.0M | $57.5M | ||
| Q2 25 | $119.5M | $79.0M | ||
| Q1 25 | $226.7M | $61.8M | ||
| Q4 24 | $686.3M | $65.1M | ||
| Q3 24 | $188.1M | $69.8M | ||
| Q2 24 | $144.7M | $54.8M |
自由现金流ACTPBH
| Q1 26 | — | — | ||
| Q4 25 | — | $75.3M | ||
| Q3 25 | — | $55.4M | ||
| Q2 25 | — | $78.2M | ||
| Q1 25 | — | $58.4M | ||
| Q4 24 | — | $63.5M | ||
| Q3 24 | — | $67.8M | ||
| Q2 24 | — | $53.6M |
自由现金流率ACTPBH
| Q1 26 | — | — | ||
| Q4 25 | — | 26.6% | ||
| Q3 25 | — | 20.2% | ||
| Q2 25 | — | 31.3% | ||
| Q1 25 | — | 19.7% | ||
| Q4 24 | — | 21.9% | ||
| Q3 24 | — | 23.9% | ||
| Q2 24 | — | 20.1% |
资本支出强度ACTPBH
| Q1 26 | — | — | ||
| Q4 25 | — | 1.1% | ||
| Q3 25 | — | 0.8% | ||
| Q2 25 | — | 0.3% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | — | 0.5% | ||
| Q3 24 | — | 0.7% | ||
| Q2 24 | — | 0.4% |
现金转化率ACTPBH
| Q1 26 | — | — | ||
| Q4 25 | — | 1.68× | ||
| Q3 25 | — | 1.36× | ||
| Q2 25 | — | 1.66× | ||
| Q1 25 | — | 1.23× | ||
| Q4 24 | — | 1.07× | ||
| Q3 24 | — | 1.28× | ||
| Q2 24 | — | 1.12× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ACT
| Premiums | $242.8M | 78% |
| Other | $69.2M | 22% |
PBH
| Womens Health | $51.8M | 18% |
| International OTC Healthcare | $47.7M | 17% |
| Gastrointestinal | $44.2M | 16% |
| Eye And Ear Care | $35.2M | 12% |
| Dermatologicals | $27.6M | 10% |
| Analgesics | $26.7M | 9% |
| Oral Care | $23.5M | 8% |
| Cough And Cold | $23.0M | 8% |
| Other Otc | $3.6M | 1% |
